May 7, 2007 - Data presented at the Pediatric Academic Societies' Annual Meeting demonstrate that premature infants with neonatal Respiratory Distress Syndrome (RDS) have a nearly 20 percent better chance of survival if they are treated with Curosurf (poractant alfa) Intratracheal Suspension rather than either of two competing surfactant therapies.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now